Multiple sclerosis treatment
The method works precisely: it suppresses only the immune cells attacking the nervous system and slows disease progression — without weakening overall immunity.
T-cell immunotherapy for multiple sclerosis
Multiple sclerosis is caused by an autoimmune process that destroys brain tissue: pro-inflammatory, myelin-reactive T-lymphocytes play a leading role. Standard treatments (hormones, cytostatics, interferons) exert a non-selective immunosuppressive effect and often lead to serious side effects.
Lymphocyte vaccination stimulates immune reactions aimed selectively at inactivating pathogenic idiotype-bearing T-lymphocytes. Once those cells are switched off, the autoimmune attack on myelin weakens.
In some patients the neurological status improves noticeably. The likely explanation is remyelination of the nerve fibres: the nervous system retains some regenerative potential.
How the treatment works
The course takes about 2 months — the exact length depends on how the body responds to the immunotherapy.
Drug preparation
Autoaggressive T-lymphocytes are isolated from your blood to create an individualized preparation.
Autoaggressive T-lymphocytes are isolated from your blood to create an individualized preparation.
Injection course
7–10 subcutaneous injections are administered over approximately 2 months.
7–10 subcutaneous injections are administered over approximately 2 months.
Selective inactivation
Vaccination triggers anti-idiotypic reactions that suppress exactly the pathogenic T-lymphocytes without depressing overall immunity.
Vaccination triggers anti-idiotypic reactions that suppress exactly the pathogenic T-lymphocytes without depressing overall immunity.
Further treatment plan
Designed individually based on the dynamics of the patient's neurological status.
Designed individually based on the dynamics of the patient's neurological status.
Clinical Study Results
Efficacy is confirmed in both relapsing-remitting and secondary progressive (chronic) forms of the disease.
stable or improved
relapsing form (n = 32): progression in only 3 patients
without progression over 2 years
progressive form (n = 39) vs. 27% in control (n = 22)
showed neurological improvement
in the progressive form; zero cases in the control group
When the method is effective
T-cell vaccination can be effective in both early and advanced stages of multiple sclerosis.
When the underlying disease is slowed down, the nervous system gets a chance to recover.
The method is selective: it does not suppress general immunity and lacks the side effects typical of standard therapy.
Questions about multiple sclerosis treatment
How does T-cell vaccination work in multiple sclerosis?
Autoaggressive T lymphocytes are isolated from the patient's blood and used to prepare a personalised vaccine. The body answers with a regulatory immune response directed against exactly those clones, without suppressing immunity in general.
Which forms of the disease is it used for?
Both relapsing and progressive forms. The schedule is chosen individually according to disease activity, MRI data and the therapy already received.
Does it replace disease-modifying therapy?
No. The method is built into the overall plan alongside the treatment prescribed by your neurologist. Stopping disease-modifying therapy on your own is not acceptable.
Can I travel for treatment from another region?
Yes. The centre is next to Moscow (Khimki, Skhodnya) and accepts patients from other regions; the first consultation can be done remotely — MRI of the brain and spinal cord with written reports and your treatment history are needed.
Where to go next
Other conditions in this area
Cost of the course
Doctors in this area
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.